---
title: 'Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape
  of Treatment for Classic Hodgkin Lymphoma'
date: '2024-12-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39672641/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241214171553&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Immune checkpoint inhibitors have transformed the future management of
  classic Hodgkin lymphoma (CHL) in the frontline and salvage settings. Both nivolumab
  and pembrolizumab have high efficacy in CHL allowing for reduction of chemotherapy
  and possibly the use of radiotherapy based on short-term follow-up. In this review
  article, we highlight recent trials enrolling patients with relapse and refractory
  classic Hodgkin lymphoma receiving monotherapy with PD-1 inhibitors as well as PD-1
  ...
disable_comments: true
---
Immune checkpoint inhibitors have transformed the future management of classic Hodgkin lymphoma (CHL) in the frontline and salvage settings. Both nivolumab and pembrolizumab have high efficacy in CHL allowing for reduction of chemotherapy and possibly the use of radiotherapy based on short-term follow-up. In this review article, we highlight recent trials enrolling patients with relapse and refractory classic Hodgkin lymphoma receiving monotherapy with PD-1 inhibitors as well as PD-1 ...